← Back to all signals
ZTS · Q3 2026

Zoetis Inc.

Reported 2026-08-06
IN-LINE
37EarnIQ signal
↘

Confidence falling

Mild quarter-over-quarter shift

Zoetis lowered its full-year guidance due to a pressured companion animal market and heightened competition.

  • ✓Guidance was lowered, with high specificity.
  • ✓Management tone registered as cautious (45/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Mixed evidence

The headline and management signals do not point in one direction (confidence falling).

EPS: reported vs expected-0.2%$1.87 vs $1.87
Revenue: reported vs expected-2.3%$2.5B vs $2.5B
Guidance specificityHighLowered
Market expectations supplied by Finnhub · Reported vs consensus estimate

Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories.

Premium intelligence

The evidence behind the signal

Full report
Management language

Why confidence moved

“Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories”
“We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development”
“As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and remain confident in the long-term fundamentals of animal health”
Guidance specificity
90/100

High specificity

Zoetis revised full-year 2026 revenue guidance to $9.120 - $9.320 billion and adjusted diluted EPS guidance to $6.15 - $6.25.

Pressure point
!

Pressured companion animal market from

0 potential deflections detected in management communication.

Narrative break

What changed

Acquisition of VitalRADS expanding Global Diagnostics offering into veterinary teleradiology and a virtual reference lab.

Q&A evidence

Management responses

No material Q&A deflections were detected.

Key positives
  • Livestock product sales increased 23% in the U.S. segment supported by strength across cattle and poultry
  • International segment revenue increased 8% on a reported basis and 6% on an organic operational basis
  • Advanced innovation pipeline with more than 12 potential blockbuster candidates and strategic expansion like the acquisition of VitalRADS
Key risks
  • Pressured companion animal market from lower clinic visits and pet owner price sensitivity
  • Persistent macro-driven price sensitivity and heightened competitive pressure on key dermatology franchise and Simparica Trio
  • Impact of generic competition on the Cerenia and Convenia brands
Topic velocity

Language versus prior quarter

M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition

What drove the EarnIQ score

Tone+6
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0